Literature DB >> 23848219

Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy.

Jin Oshikawa1, Yoshiyuki Toya, Satoshi Morita, Masataka Taguri, Kazushige Hanaoka, Toshio Hasegawa, Kazo Kaizu, Kouju Kamata, Shuzo Kobayashi, Takayasu Ohtake, Takeo Sato, Gen Yasuda, Kenjiro Kimura, Satoshi Umemura.   

Abstract

Diuretics or calcium channel blockers (CCBs) are used concomitantly with an angiotensin II receptor blocker (ARB). However, it is not established which ARB-based combination therapy is the most effective and safe. This prospective randomized open-label study compared the efficacy and safety of a fixed-dose tablet of losartan (LST)-hydrochlorothiazide (HCTZ) (n = 99) and LST-amlodipine (AML) (n = 77) in Japanese patients whose hypertension was uncontrolled by ARB monotherapy. Blood pressure changed similarly over the 12-month study period. Only LST-HCTZ significantly increased serum uric acid (SUA) in patients with low baseline SUA (<5.6 mg/dL) but not in patients with high baseline SUA.

Entities:  

Keywords:  Angiotensin receptor antagonists; combination; comparative study; drug therapy; hypertension; sodium chloride symporter inhibitors

Mesh:

Substances:

Year:  2013        PMID: 23848219     DOI: 10.3109/10641963.2013.810227

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  7 in total

1.  Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg.

Authors:  Hiromi Rakugi; Takuya Tsuchihashi; Kazuyuki Shimada; Hirotaka Numaguchi; Chisato Nishida; Hiroya Yamaguchi; Masayoshi Shirakawa; Kyoichi Azuma; Kenji P Fujita
Journal:  Hypertens Res       Date:  2015-02-26       Impact factor: 3.872

2.  The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.

Authors:  Punnaka Pongpanich; Pasvich Pitakpaiboonkul; Kullaya Takkavatakarn; Kearkiat Praditpornsilpa; Somchai Eiam-Ong; Paweena Susantitaphong
Journal:  Int Urol Nephrol       Date:  2018-10-15       Impact factor: 2.370

3.  Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients.

Authors:  Alberto F Rubio-Guerra; Ana K Garro-Almendaro; Cesar I Elizalde-Barrera; Juan A Suarez-Cuenca; Montserrat B Duran-Salgado
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-12-08

Review 4.  Thiazide Diuretic-Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials.

Authors:  Jill J Hall; Dean T Eurich; Danielle Nagy; Lisa Tjosvold; John-Michael Gamble
Journal:  J Gen Intern Med       Date:  2020-03-10       Impact factor: 5.128

5.  Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study.

Authors:  Shih-Yi Lin; Cheng-Li Lin; Cheng-Chieh Lin; Wu-Huei Hsu; Chung-Y Hsu; Chia-Hung Kao
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

6.  Renoprotective effects of renin-angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients: A PRISMA-compliant meta-analysis.

Authors:  Yiming Cheng; Rongshuang Huang; Sehee Kim; Yuliang Zhao; Yi Li; Ping Fu
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

7.  The association of smoothness index of central blood pressure with ambulatory carotid femoral pulse wave velocity after 20-week treatment with losartan in combination with amlodipine versus hydrochlorothiazide.

Authors:  Jinho Shin; Hae Young Lee; Wook Jin Chung; Ho Joong Youn; Eun Joo Cho; Ki Chul Sung; Shung Chull Chae; Byung Su Yoo; Chang Gyu Park; Soon-Jun Hong; Taek Jong Hong; Dong-Ju Choi; Jong Won Ha; Young Jo Kim; Young Keun Ahn; Myeong-Chan Cho; Soon Kil Kim; Sungha Park; Il-Suk Sohn; Chong-Jin Kim
Journal:  J Hypertens       Date:  2019-12       Impact factor: 4.844

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.